Eli Lilly India News and Activities
Presence
Headquarters: India
Eli Lilly is one of the...
- Forbes Global 2000 (#138);
- Fortune 500 (#127);
- Global Fortune 500 (#336);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly is a company listed under the stock ticker LLY (US).
Eli Lilly has a direct presence in 18 countries.Eli Lilly has 26 subsidiaries including Adverum Biotechnologies, Akouos and CrossBridge Bio.
They are in:
- Pharmaceuticals70%
- Biotechnology19%
- Other11%
Acquisition, funding and merger involving Eli Lilly.
- Eli Lilly has announced the acquisition of Curevo Vaccine (posted on May 26 2026).
- Eli Lilly has announced the acquisition of LimmaTech Biologics (posted on May 26 2026).
- Eli Lilly has acquired EngageBio (posted on May 22 2026).
- Eli Lilly has acquired Ventyxbio (posted on May 4 2026).
- Eli Lilly has announced the acquisition of Ajax Therapeutics (posted on April 28 2026).
- Eli Lilly has announced the acquisition of Kelonia Therapeutics (posted on April 20 2026).
- Eli Lilly has acquired CrossBridge Bio (posted on April 20 2026).
- Eli Lilly has announced the acquisition of Centessa Pharmaceuticals (posted on March 31 2026).
- Eli Lilly has announced the acquisition of Orna Therapeutics (posted on February 11 2026).
- Eli Lilly has announced the acquisition of Ventyxbio (posted on January 8 2026).
- Eli Lilly has acquired Adverum Biotechnologies (posted on December 10 2025).
- Adverum Biotechnologies and Eli Lilly have announced they will merge (posted on November 26 2025)..
- Eli Lilly has acquired Verve Therapeutics (posted on July 25 2025).
- Eli Lilly has announced the acquisition of Verve Therapeutics (posted on June 17 2025).
- Eli Lilly has announced the acquisition of SiteOne Therapeutics (posted on May 29 2025).
- Eli Lilly has announced the acquisition of Scorpion Therapeutics (posted on January 23 2025).
- Eli Lilly has acquired Morphic Therapeutic (posted on August 20 2024).
- See more news about Eli Lilly Hide news involving Eli Lilly
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Eli Lilly India
- Abha Mahalka, Director
- Narinder Seth, Vice President, Information Technology
- Yusuf Bilal Birinc, Chief Financial Officer and One India Hub
Popular executive movements at Eli Lilly India
- Suchi Chauhan who was Senior Manager, Human Resources, becomes Associate Director, Human Resources (posted on March 23 2026).
- Ravi Iyer has joined the company as Associate Director, Market Research, Business Insights and Analytics (posted on March 16 2026).
Popular executive movements at Eli Lilly
- Jean Santana, who was Senior Director, Human Resources Business Partner, Manufacturing and Quality, is promoted to Senior Director, Global People Strategy, Manufacturing and Quality (posted on May 13 2026).
- Jasmine Leong, who was Senior Director of International Market Alzheimer's Diagnostics, is promoted to Executive Director, International Brand, Alzheimer (posted on May 4 2026).
- Fatemeh Akhlaghi has joined the company as Executive Director, Clinical Pharmacology (posted on May 4 2026).
Click here to view some more movements at Eli Lilly
Create your alert
to follow the executive moves at Eli Lilly India.
Pharmaceuticals
Eli Lilly has 1,913 competitors including Sanofi (France), Moderna (United States (USA)) and Novartis (Switzerland).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Eli Lilly India
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks | Eli Lilly and Company
- Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity | Eli Lilly and Company
- Lilly Statement on New 340B Litigation | Eli Lilly and Company
- Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose | Eli Lilly and Company
Social media about Eli Lilly India
- Eli Lilly India on Wikipedia, Google News & Yahoo Finance
- Eli Lilly India on LinkedIn, X (Twitter) & YouTube
